Increased interleukin-18 content and angiogenic activity of sera from diabetic (Type 2) patients with background retinopathy.
暂无分享,去创建一个
Anna Lipińska | E. Skopińska-Różewska | J. Szaflik | A. Lipińska | J. Chorostowska-Wynimko | Joanna Chorostowska-Wynimko | P. Skopiński | Piotr Skopiński | Ewa Rogala | Barbara Duda-Król | Ewa Sommer | Jerzy Szaflik | Iwona Partyka | Ewa Skopińska-Rózewska | I. Partyka | B. Duda-Król | E. Sommer | E. Rogala | J. Szaflik
[1] R. Auerbach,et al. Lymphocyte-induced angiogenesis: a quantitative and sensitive assay of the graft-vs.-host reaction , 1975, The Journal of experimental medicine.
[2] B. de Geus,et al. Transforming growth factor-beta and the glomerular extracellular matrix in renal pathology. , 1994, The Journal of laboratory and clinical medicine.
[3] G. Trinchieri,et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. , 1998, The Journal of clinical investigation.
[4] U. Demkow,et al. Angiogenic activity and IL‐8 concentrations in peritoneal fluid and sera in endometriosis , 2002, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[5] C. Tsalamandris,et al. Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. , 2002, Diabetes care.
[6] E. Vlková,et al. Polymorphism R25P in the gene encoding transforming growth factor-beta (TGF-beta1) is a newly identified risk factor for proliferative diabetic retinopathy. , 2002, American journal of medical genetics.
[7] M. Kurimoto,et al. Interleukin‐18 acts as an angiogenesis and tumor suppressor , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[8] Masafumi Koga,et al. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. , 2003, Metabolism: clinical and experimental.
[9] R. Merendino,et al. Serum Levels of Interleukin-18 and sICAM-1 in Patients Affected by Breast Cancer: Preliminary Considerations , 2001, The International journal of biological markers.
[10] R. Marfella,et al. Inflammatory Cytokine Concentrations Are Acutely Increased by Hyperglycemia in Humans: Role of Oxidative Stress , 2002, Circulation.
[11] N. Horwood,et al. Interleukin-18: perspectives on the newest interleukin. , 1998, Cytokine & growth factor reviews.
[12] J. Forrester,et al. Regulation of transforming growth factor-beta, basic fibroblast growth factor, and vascular endothelial cell growth factor mRNA in peripheral blood leukocytes in patients with diabetic retinopathy. , 1999, Metabolism: clinical and experimental.
[13] A. Koch,et al. Evidence of IL-18 as a Novel Angiogenic Mediator1 , 2001, The Journal of Immunology.
[14] H. Mühl,et al. Lack of Interferon-γ Production Despite the Presence of Interleukin-18 During Cutaneous Wound Healing , 2000, Molecular medicine.
[15] R. A. Mahmoud,et al. Increased serum levels of interleukin-18 in patients with diabetic nephropathy. , 2004, The Italian journal of biochemistry.
[16] U. Demkow,et al. Suppression of angiogenic activity of sera from diabetic patients with non-proliferative retinopathy by compounds of herbal origin and sulindac sulfone. , 2004, International journal of molecular medicine.
[17] K. Sfiridaki,et al. Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival. , 2004, Leukemia research.
[18] S. Lee,et al. TGF-betas synthesized by RPE cells have autocrine activity on mesenchymal transformation and cell proliferation. , 2001, Yonsei medical journal.